Stifel Financial
JANX icon

Stifel Financial’s Janux Therapeutics JANX Stock Holding History

Stifel Financial’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,173
Closed -$197K – 3762
2026
Q1 		$197K Buy
+14,173
New +$194K ﹤0.01% 3448
2025
Q4 		– Sell
-11,307
Closed -$276K – 3633
2025
Q3 		$276K Buy
+11,307
New +$275K ﹤0.01% 3166

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Stifel Financial's JANX Position: Q2 2026 in Review

Stifel Financial sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 14,173 shares — an estimated $197K sold.

Stifel Financial first reported a position in JANX in Q3 2025 and held it in 2 quarters. The position peaked at $276K in Q3 2025. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Stifel Financial reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Stifel Financial sold 14,173 Janux Therapeutics shares in Q2 2026, an estimated $197K.
  • Stifel Financial first reported a position in Janux Therapeutics in Q3 2025 and held it in 2 quarters.
  • Stifel Financial's Janux Therapeutics position peaked at $276K in Q3 2025.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.